Patients Practitioners Medicines About Novo Nordisk Contact News and videos Novo Nordisk / Medicines / Diabetes / NovoMix ® 70 (biphasic insulin aspart) Medicines Diabetes Fiasp ® (insulin aspart) GlucaGen ® (glucagon) Insulatard ® (isophane (NPH) human insulin) Levemir ® (insulin detemir) NovoMix ® 30 (biphasic insulin aspart) NovoMix ® 50 (biphasic insulin aspart) NovoMix ® 70 (biphasic insulin aspart) NovoNorm ® (repaglinide) NovoRapid ® (insulin aspart) Ozempic ® (semaglutide) Rybelsus ® (semaglutide tablets) Ryzodeg ® (insulin degludec / insulin aspart) Tresiba ® (insulin degludec) Victoza ® (liraglutide) Xultophy ® (insulin degludec / liraglutide) Growth hormone Haemophilia Obesity Hormone Replacement Therapy Delivery systems and needles Availability abroad NovoMix ® 70 (biphasic insulin aspart) What is NovoMix ® 70? NovoMix ® 70 is a modern insulin (insulin analogue) with both a fast-acting and a medium-acting effect, in the ratio 70/30. Modern insulin products are improved versions of human insulins. NovoMix ® 70 is used to reduce high blood sugar in patients with diabetes mellitus (diabetes). Diabetes is a condition in which your body does not make enough insulin to control your blood sugar. NovoMix ® 70 can be used in combination with metformin. NovoMix ® 70 will start to lower your blood sugar about 10 to 20 minutes after you inject it. The maximum effect occurs 1 to 4 hours after the injection and lasts for 14 - 24 hours. NovoMix ® 70 contains 70% dissolved insulin aspart and 30% insulin aspart protamine in crystalline form. Who is NovoMix ® 70 for? NovoMix ® 70 can be used to treat diabetes mellitus (diabetes) in adults. Form of administration NovoMix ® 70 100 units / ml suspension for injection in a pre-filled pen (FlexPen ® ). Patient information leaflet NovoMix ® 70 FlexPen ® 100 U / ml, suspension for injection in a pre-filled pen Who we are Novo Nordisk is an international company with over 95 years of experience in diabetes care. The head office is located in Denmark. The company offers a wide range of innovative medicines, advanced delivery systems and services to optimize the care and treatment of people with diabetes. In addition, Novo Nordisk is a leader in coagulation disorders, growth hormone therapy and hormone replacement therapy. Novo Nordisk has approximately 43,100 employees in 80 countries and is represented in more than 170 countries. Novo Nordisk websites novonordisk.com Or choose: Local websites Novo Nordisk worldwide © Novo Nordisk BV 2020 Privacy Statement Disclaimers Processing of personal data, side effects and other safety information Cookie Settings